GATA-Binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and Mammaglobin a in triple-negative breast cancer by Immunohistochemistry

Histopathology

Volumn 67, Issue 2, 2015, Pages 245-254

  Huo, Lei ^a   Gong, Yun ^a   Guo, Ming ^a   Gilcrease, Michael Z ^a   Wu, Yun ^a   Zhang, Hong ^a   Zhang, Jinxia ^a   Resetkova, Erika ^a   Hunt, Kelly K ^a   Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

GATA 3; GCDFP 15; Immunohistochemistry; Mammaglobin; Squamous; Triple negative

Indexed keywords

GATA BINDING PROTEIN 3; GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN A; TUMOR MARKER; UNCLASSIFIED DRUG; CARRIER PROTEIN; GATA3 PROTEIN, HUMAN; GLYCOPROTEIN; PIP PROTEIN, HUMAN; TRANSCRIPTION FACTOR GATA 3; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CONTROLLED STUDY; DISEASE MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER; ENZYME IMMUNOASSAY; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; STAINING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARRIER PROTEINS; FEMALE; GATA3 TRANSCRIPTION FACTOR; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMAGLOBIN A; MIDDLE AGED; NEOPLASM PROTEINS; STAINING AND LABELING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84923862572     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12645     Document Type: Article

References (41)

1. Wick MR. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum. Pathol. 1989; 20; 281-287.
2. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am. J. Clin. Pathol. 2007; 127; 103-113.
3. Huo L, Zhang J, Gilcrease MZ et al. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 2013; 62; 267-274.
4. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Curr. Opin. Cell Biol. 2008; 20; 164-170.
5. Ordóñez NG. Value of GATA3 immunostaining in tumor diagnosis: a review. Adv. Anat. Pathol. 2013; 20; 352-360.
6. Hoch RV, Thompson DA, Baker RJ, Weigel RJ. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int. J. Cancer 1999; 84; 122-128.
7. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127; 1041-1055.
8. Asselin-Labat ML, Sutherland KD, Barker H et al. GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 2007; 9; 201-209.
9. Albergaria A, Paredes J, Sousa B et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009; 11; R40.
10. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod. Pathol. 2010; 23; 654-661.
11. Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am. J. Clin. Pathol. 2012; 138; 57-64.
12. Miettinen M, McCue PA, Sarlomo-Rikala M et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2014; 38; 13-22.
13. Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am. J. Clin. Pathol. 2014; 142; 64-71.
14. Krings G, Nystrom M, Mehdi I, Vohra P, Chen YY. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum. Pathol. 2014; 45; 2225-2232.
15. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
16. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
17. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 2003; 100; 8418-8423.
18. Mehra R, Varambally S, Ding L et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005; 65; 11259-11264.
19. Cimino-Mathews A, Subhawong AP, Illei PB et al. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum. Pathol. 2013; 44; 1341-1349.
20. Liu H, Shi J, Prichard JW, Gong Y, Lin F. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Am. J. Clin. Pathol. 2014; 141; 648-655.
21. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; 907-922.
22. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007; 131; 18-43.
23. Gruver AM, Amin MB, Luthringer DJ et al. Selective immunohistochemical markers to distinguish between metastatic highgrade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch. Pathol. Lab. Med. 2012; 136; 1339-1346.
24. Chang A, Amin A, Gabrielson E et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am. J. Surg. Pathol. 2012; 36; 1472-1476.
25. Han JH, Kang Y, Shin HC et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch. Pathol. Lab. Med. 2003; 127; 1330-1334.
26. Wang LJ, Greaves WO, Sabo E et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 505-511.
27. Zafrakas M, Petschke B, Donner A et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006; 6; 88.
28. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod. Pathol. 2007; 20; 208-214.
29. Wang Z, Spaulding B, Sienko A et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int. J. Clin. Exp. Pathol. 2009; 2; 384-389.
30. Ting CN, Olson MC, Barton KP, Leiden JM. Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 1996; 384; 474-478.
31. Grote D, Souabni A, Busslinger M, Bouchard M. Pax 2/8-regulated GATA 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 2006; 133; 53-61.
32. Lim KC, Lakshmanan G, Crawford SE, Gu Y, Grosveld F, Engel JD. GATA3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat. Genet. 2000; 25; 209-212.
33. Tsarovina K, Pattyn A, Stubbusch J et al. Essential role of GATA transcription factors in sympathetic neuron development. Development 2004; 131; 4775-4786.
34. Grigorieva IV, Mirczuk S, Gaynor KU et al. GATA3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm 2. J. Clin. Invest. 2010; 120; 2144-2155.
35. Kaufman CK, Zhou P, Pasolli HA et al. GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev. 2003; 17; 2108-2122.
36. Higgins JP, Kaygusuz G, Wang L et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am. J. Surg. Pathol. 2007; 31; 673-680.
37. Schwartz LE, Begum S, Westra WH, Bishop JA. GATA3 immunohistochemical expression in salivary gland neoplasms. Head Neck Pathol. 2013; 7; 311-315.
38. Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP. Cutaneous and mammary apocrine carcinomas have different immunoprofiles. Hum. Pathol. 2014; 45; 320-326.
39. Esheba GE, Longacre TA, Atkins KA, Higgins JP. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am. J. Surg. Pathol. 2009; 33; 347-353.
40. So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod. Pathol. 2013; 26; 1365-1370.
41. Yi M, Huo L, Koenig KB et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann. Oncol. 2014; 25; 1004-1011.